Literature DB >> 26187895

Direct uptake of Antagomirs and efficient knockdown of miRNA in primary B and T lymphocytes.

Claudia Haftmann1, René Riedel1, Martina Porstner2, Jürgen Wittmann2, Hyun-Dong Chang1, Andreas Radbruch1, Mir-Farzin Mashreghi3.   

Abstract

Depending on their physiological expression level, microRNAs (miRNA) address different target genes, thus have different biological functions. To identify these, the physiological expression has to be blocked. Here, we describe the use of inhibitory cholesterol-modified oligonucleotides (Antagomirs) to inhibit miRNAs selectively in primary human and murine T and B lymphocytes. Due to their lipophilic cholesterol tag Antagomirs enter primary lymphocytes efficiently and quantitatively. We show here that at concentrations of 0.125 to 1μM, Antagomirs selectively inhibit expression of their target miRNA up to 99.5% without affecting cell viability.
Copyright © 2015. Published by Elsevier B.V.

Entities:  

Keywords:  Antagomir; Murine and human primary lymphocytes; miRNA knockdown

Mesh:

Substances:

Year:  2015        PMID: 26187895      PMCID: PMC4655414          DOI: 10.1016/j.jim.2015.07.006

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


Introduction

Sequence-specific, genetic inhibition of miRNA is the only way to determine its role in physiology, at the level expressed in a given cell (Stenvang et al., 2012). So far, introduction of specific inhibitory oligonucleotides into the cell had required viral and non-viral transfection protocols, the latter dependent on cationic lipids, polymer reagents or electroporation (Mantei et al., 2008). This poses a fundamental problem for the analysis of miRNA in primary T and B lymphocytes. First, they are highly refractory to non-viral transfection methods, and second, they are activated by viral infection, introducing an artifactual bias on the analysis of miRNA (Ziegler et al., 2013). Here, we describe a detailed protocol for the direct introduction of Antagomirs into murine and human primary T (Stittrich et al., 2010, Haftmann et al., 2015, Warth et al., 2015) and B lymphocytes (Knoll et al., 2013, Porstner et al., 2015) solving this fundamental problem. Antagomirs are 20–25 nucleotide long, single stranded RNA molecules, with a sequence complementary to an entire mature miRNA (Krutzfeldt et al., 2005). Their backbone consists of 2′-O-methyl (2′-O-Me) single stranded oligoribonucleotides and partially modified phosphorothioate (PS) linkers. Antagomirs have a cholesterol-tag at their 3′ end, which enables their efficient direct uptake via the cell membrane into viable cells. At concentrations of 0.125 to 1 μM, Antagomirs selectively inhibit their target miRNA up to 99.5%, without affecting viability of the T and B lymphocytes, or activating them.

Materials and methods

Mice

C57BL/6 mice were housed and bred under specific pathogen-free conditions. Mice were handled in accordance with good animal practice as defined by German animal welfare bodies and sacrificed by cervical dislocation.

Cell culture

Naïve CD4+ T cells and CD19+ B cells were isolated from spleens of 6–10 week old mice (magnetic activated cell sorting (MACS) microbead technology, Miltenyi Biotech). For T helper 1 lymphocyte (Th1) polarization, 3 × 106 naïve CD4+ T cells were cultured and stimulated with plate-bound αCD3/αCD28 (3 μg/ml, eBioscience), in the presence of irradiated (30 Gy) CD90-depleted splenocytes from C57BL/6 mice as antigen-presenting cells and recombinant IL-12 (5 ng/ml; R&D Systems) and anti-IL-4 (11B11) antibody. Under this condition, viable Th1 cells were restimulated every 6 days for three rounds to induce repeatedly activated Th1 cells (Haftmann et al., 2015). Ex vivo isolated murine CD19+ B cells were activated with 1 μg/ml lipopolysaccharide (LPS). Human peripheral blood mononuclear cells were isolated from whole blood by density gradient centrifugation and fluorescently labeled for CD4 and CD19.

Reagents

Lyophilized Antagomirs were custom synthesized according to Krutzfeldt et al. (2005) (Dharmacon, GE Healthcare). Antagomir sequences are as follows: Antagomir-scr 5-mU(*)mC(*)mAmCmGmCmAmGmAmUmUmCmAmUmAmA(*)mC(*)mG(*)mU(*)-3-Chol; and Antagomir-148a 5-mA(*)mC(*)mAmAmAmGmUmUmCmUmGmUmAmGmUmGmCmAmC(*)mU(*)mG(*)mA(*)-3-Chol. All ribonucleotides are 2′-O-methyl modified (mN) and (*) represents a phosphorothioate modification of the backbone. At the 3′-end of the oligonucleotides, a cholesterol molecule was added. Lyophilized Antagomirs were resolved in RNase-free water at the desired concentration at room temperature for 30 min with slight shaking.

Antagomir treatment

Naïve or resting primary murine or human T and B lymphocytes as well as murine repeatedly activated Th1 cells were washed with cold PBS at 300 g for 8 min. Lymphocytes (up to 1 × 107 cells/ml) were resuspended in 0.25 volumes of final culture volume of serum-free medium (ACCELL, Dharmacon) supplemented with Antagomir-148a or Antagomir-scr in different concentrations. Lymphocytes were incubated for 2 h at 5% CO2, 95% humidity and 37 °C. After incubation, repeatedly activated murine Th1 cells were stimulated with plate-bound αCD3/αCD28 (3 μg/ml, eBioscience). CD19+ murine B cells were activated with 1 μg/ml LPS (see also the Cell culture section). Both cell types were further cultured in RPMI 1640 (Gibco®, Life Technologies) cell culture medium with 10% FCS, 100 U/ml Penicillin/Streptomycin, 50 μM β-mercaptoethanol in vitro (RPMI was added in fourfold excess to the lymphocytes in the ACCELL/Antagomir medium). A detailed protocol for Antagomir treatment is provided in Table 1.
Table 1

Protocol — procedure and timing.

ProtocolComments
Pre-incubation of lymphocytes with Antagomirs, timing 2.5 h
1Wash lymphocytes (naïve or resting primary T or B cells) with cold PBS and centrifuge at 300 g for 8 min.
2Resuspend lymphocytes (up to 1 ∗ 107 cells/ml) in 0.25 volumes of final culture volume of serum-free medium, e.g., ACCELL (Dharmacon) (i.e., if cell culture is carried out in 5 ml, resuspend lymphocytes in 1.25 ml serum-free medium).Critical: serum-free medium increases the efficiency of Antagomir uptake from the medium. The cholesterol-coupled Antagomirs will attach to the cell surface and are subsequently incorporated.
3Dilute Antagomirs at the desired and titrated concentration.Critical: even at only moderate miRNA knockdown efficiency there may already be visible phenotypical changes and impact on potential targets. Too high concentrations of Antagomirs may lead to off-target effects. Therefore, a titration of the Antagomirs and determination of suitable analysis time points in different culture settings is highly recommended prior to experimental procedures.
4Gently mix samples and incubate for 2 h at 5% CO2, 95% humidity and 37 °C. Meanwhile prepare stimulating and differentiating medium for further cell culture.



Stimulation and culture of Antagomir-treated lymphocytes in vitro
5Add 0.75 volumes of serum-containing culture medium supplemented with all necessary cytokines and stimuli to culture wells/plates (e.g., in this study, repeatedly activated Th1 cells were restimulated with plate-bound αCD3/αCD28 and recombinant IL-12 and anti-IL-4 antibody).Antagomir uptake does not depend on reactivation of lymphocytes. Resting lymphocytes treated with Antagomirs can also be monitored (e.g., Fig. 1d) and analyzed.
6Add 0.25 volumes of Antagomir-treated cells to the medium and incubate at 5% CO2, 95% humidity and 37 °C for the desired time.Critical: Determine the most suitable analysis time point prior to experimental procedures, e.g., by expression kinetics of miRNA, target genes and usage of reporter gene assays.



Control knockdown efficiency by quantitative real-time PCR analysis
7At the end of the experimental procedure, perform the desired analysis and take an aliquot of the cells to determine knockdown efficiency of Antagomirs (and their potential impact on targets) by qRT-PCR analysis or Northern Blots (and/or protein detection).

Detection of Antagomir incorporation

Fluorescein-conjugated Antagomirs were used for quantification of Antagomir incorporation and detected by flow cytometry (MACSQuant, Miltenyi Biotec) or image stream cytometry (Amnis ImageStreamX MKII, Merck Millipore).

RNA extraction and quantitative PCR analysis

Total RNA was isolated with Direct-zol RNA kit (Zymo Research). Mature miR-148a, miR-148b, miR-152, miR-182, miR-320 and U6 small nuclear RNA (snRNA) were detected by quantitative PCR with a Taqman MicroRNA Reverse Transcription kit in combination with TaqMan MicroRNA Assays (Life Technologies) according to the manufacturer's recommendations. For normalization, the expression values were compared to values of snU6 by the change-in-threshold method (2 − ΔCT) (Haftmann et al., 2015). Reverse transcription of mRNA was performed using the Reverse Transcription kit (Life Technologies, Germany) and cDNA was quantified by SYBR Green based real-time PCR (Roche) using the following primer pairs: murine hypoxanthine guanine phosphoribosyltransferase (HPRT) forward 5′-TCCTCCTCAGACCGCTTTT-3′, HPRT reverse 5′-CATAACCTGGTTCATCATCGC-3′, murine BIM forward 5′-CCCGGAGATACGGATTGCA-3′ and BIM reverse 5′-AACACCCTCCTTGTGTAAGTTTCGT-3′ (Haftmann et al., 2015). For normalization, the expression values were compared to values of HPRT by the change-in-threshold method (2 − ΔCT) (Livak and Schmittgen, 2001).

Results and discussion

Here, we show a simple and reliable method to inhibit the physiological function of miRNA in T and B lymphocytes, which are difficult to transfect by conventional methods. The introduction of Antagomirs does not require the use of transfection vehicles or electroporation. Antagomirs act in the cytoplasm by inhibiting the activity of their target miRNA.

Efficiency of Antagomir uptake in primary murine and human T and B cells

To introduce Antagomirs into ex vivo isolated murine B and T lymphocytes, the cells were incubated with fluorescein-conjugated Antagomir for 2 h in serum-free medium. Uptake of cholesterol-containing oligonucleotides is highly efficient in serum-free medium (Petrova et al., 2012). The Antagomir (Antagomir-scr) was designed not to target any known miRNA (Stittrich et al., 2010, Knoll et al., 2013, Haftmann et al., 2015, Porstner et al., 2015, Warth et al., 2015). Fluorescein-conjugated Antagomir-scr was incorporated in a concentration dependent manner after 2 h incubation in primary B and T cells (Fig. 1a). Ex vivo isolated T and B cells had taken up the Antagomir quantitatively and a fluorescein signal was detectable even 3 days after activation of the cells despite proliferation (Fig. 1b). Strong fluorescence was detected at d0 and was most likely due to surface-bound Antagomir-scr which was lost by d1. The Antagomirs taken up by the cells were detectable within T as well as B lymphocytes and do not co-localize with CD4 or CD19 surface staining (Fig. 1c). Localization of Antagomirs in the cytoplasm after in vivo application has been demonstrated by others (Krutzfeldt et al., 2007), and suggests why nuclear miRNA precursors are not affected by Antagomirs (Krutzfeldt et al., 2005).
Fig. 1

Antagomirs efficiently enter primary lymphocytes, are localized in the cytoplasm and show low cytotoxicity. Ex vivo isolated (MACS Technology, Miltenyi Biotech, Germany) unstimulated CD4+ T cells and unstimulated CD19+ B cells were treated with fluorescein-coupled non-targeting control Antagomir (Antagomir-scr) or incubated in serum-free medium without addition of Antagomir (Incubation ctrl). a) Cells were treated with concentrations of 0.125 to 2 μM of fluorescein-coupled Antagomir-scr for 2 h in serum-free medium and fluorescence was analyzed by flow cytometry; b) cells were treated with a concentration of 1 μM of fluorescein-coupled Antagomir-scr, washed after 2 h of incubation with PBS, cultured in FCS-containing RPMI medium for 3 days and fluorescence was analyzed by flow cytometry, d0 = cells after 2 h of incubation; c) cytoplasmic localization of fluorescein-coupled Antagomir-scr in live murine CD4+ T cells, murine CD19+ B cells, human CD4+ T cells and human CD19+ B cells was determined by single cell immunofluorescence analysis (Amnis ImageStreamX MKII, Merck Millipore) 24 h after incubation with Antagomirs, BF — bright field, CD4/CD19 — surface staining; d) viability of murine CD4+ Th1 cells and CD19+ B cells after treatment with different concentrations of Antagomir-scr in serum-free medium for 2 h. Viability was determined by propidium iodide staining, analyzed by flow cytometry and normalized to cells that were incubated in serum-free medium without addition of Antagomir.

When Antagomirs were applied at concentrations of 1 μM and for 3 h of incubation in serum-free medium, more than 95% of the T and B lymphocytes were viable, as determined by propidium iodide staining (Fig. 1d). An increase of the Antagomir concentration to 16 μM resulted in reduced viability of T cells to below 50%, while still more than 85% of the B cells were viable. After incubation with Antagomir concentrations of 1 μM cell viability is maintained over several days allowing for functional assays in vitro or adoptive cell transfer in murine models (Stittrich et al., 2010, Knoll et al., 2013, Haftmann et al., 2015, Porstner et al., 2015, Warth et al., 2015). Contrastingly, the introduction of antisense oligonucleotides by nucleofection or lipofection results in high variability in terms of efficiency and negatively affects cell viability and are therefore less reliable methods for miRNA knockdown in experimental settings.

Efficiency and specificity of miRNA-knockdown by Antagomir treatment

To assess the specific on-target activity of Antagomirs taken up by T and B lymphocytes, we used a non-fluorescently labeled Antagomir targeting miR-148a (Antagomir-148a). miR-148a is highly expressed in repeatedly activated murine Th1 lymphocytes following restimulation with anti-CD3 and anti-CD28 antibodies (reactivated 4 times in weekly intervals) (Haftmann et al., 2015) and in LPS-activated CD19+ B lymphocytes (Porstner et al., 2015). Repeatedly activated Th1 cells were incubated for 2 h in serum-free medium with Antagomir-148a, a non-targeting non-fluorescently labeled control Antagomir (Antagomir-scr) or without Antagomir (Incubation ctrl). Expression of miR-148a was quantitated by real-time PCR analysis. Expression of miR-148a was inhibited selectively and in a dose-dependent fashion by the Antagomir-148a at concentrations between 0.125 and 1 μM in both T and B lymphocytes. Expression of miR-148a was completely blocked in T lymphocytes at 1 μM, and inhibited by 87% in B lymphocytes at 2 μM (Fig. 2a, b). Inhibition of miR-148a results in an about 2-fold increase in the mRNA level of its target gene Bim, already at a concentration of 0.125 μM Antagomir-148a (Fig. 2c), demonstrating the specific Antagomir effect on miRNA function primarily via RNAi-independent degradation of miRNA (Krutzfeldt et al., 2007). For miRNA with unknown target genes, we suggest to use reporter gene assays for testing the functionality of Antagomir treatment (Davis et al., 2006). Such reporter constructs have specific miRNA binding sites in their 3′ untranslated region and are subsequently subjected to miRNA-mediated downregulation, which should be restored by Antagomir treatment (Davis et al., 2006).
Fig. 2

Antagomirs silence miR-148a with a concentration-dependent efficacy in T and B cells and with high miRNA specificity. miR-148a expression was analyzed in a) repeatedly activated Th1 cells (Niesner et al., 2008, Haftmann et al., 2015) on day 3 after reactivation with 3 μg/ml of plate-bound αCD3/αCD28 and b) ex vivo isolated CD19+ B cells on day 4 after activation with 1 μg/ml LPS. The cells were treated with indicated concentrations of Antagomir-148a, a non-targeting control Antagomir (Antagomir-scr) or incubated in serum-free medium without addition of Antagomir (Incubation ctrl). miRNA expression was determined by qRT-PCR analysis and normalized to small nuclear RNA U6 (snU6); c) analysis of Bim expression on day 3 after restimulation of repeatedly activated Th1 cells treated with various concentrations of Antagomir-148a, Antagomir-scr or without Antagomir (Incubation ctrl), determined by qRT-PCR analysis and normalized to hypoxanthine-guanine phosphoribosyltransferase (HPRT) expression; d) miR-148a expression in repeatedly activated Th1 cells (Niesner et al., 2008, Haftmann et al., 2015) on day 3 after reactivation either treated with 1 μM Antagomir-148a or Antagomir-scr during different incubation times in serum-free medium in comparison to repeatedly activated Th1 cells before restimulation (Th1 rep. w/o). Repeatedly activated Th1 cells were restimulated with 3 μg/ml of plate-bound αCD3/αCD28; e) sequence homology of miR-148a, miR-148b and miR-152 and complementarity to Antagomir-148a (red indicates the miRNA seed region and blue the mismatches between miR-148b and miR-152 compared to miR-148a); f) expression levels of miR-148a, miR-148b, miR-152, miR-182 and miR-320 in repeatedly activated Th1 cells treated with 1 μM Antagomir-148a or Antagomir-scr on day 3 after restimulation with 3 μg/ml of plate-bound αCD3/αCD28, determined by qRT-PCR analysis and normalized to snU6.

To determine the optimal incubation time for miR-148a knockdown, repeatedly activated Th1 lymphocytes were incubated in serum-free medium with either 1 μM Antagomir-148a or Antagomir-scr from 5 min up to 4 h. After the various incubation periods, cells were further stimulated with αCD3 and αCD28 antibodies for 3 days. Expression of miR-148a was inhibited by 99.5% after an incubation time of 2 h and resembled miR-148a levels observed in repeatedly reactivated Th1 lymphocytes before restimulation (Fig. 2d). Five minutes of incubation with Antagomirs is sufficient to achieve a ~ 94% knockdown of miR-148a three days after activation. This may be sufficient for experiments in which prolonged serum starvation leads to massive cell death. The specificity of Antagomir action was assessed by comparing the impact of Antagomir-148a treatment on the levels of miR-148a, miR-148b, miR-152, miR-182 and miR-320 in repeatedly reactivated T lymphocytes. Mir-148a, miR-148b and miR-152 share the same seed sequence (Fig. 2e). Antagomir-148a inhibited expression of miR-148a by 98%, miR-148b by 80% and miR-152 by 60%. Expression of miR-182 and miR-320 was not inhibited (Fig. 2f). Knockdown of the target miRNA is highly sequence-specific and miRNAs with unrelated sequence remain unaffected. Even two (miR-148b) or three mismatches (miR-152) (Fig. 2e) in closely related miRNA sequences reduce the knockdown efficiencies markedly. Off-target effects on miRNA with related sequences must be tested for each individual Antagomir. Of note, the efficiency of miRNA knockdown can be alternatively tested by Northern Blots (Krutzfeldt et al., 2005, Davis et al., 2006) instead of quantitative real time-PCR (qRT-PCR). Antagomirs are suitable for selective miRNA inhibition in resting as well as activated lymphocytes. This method is efficient, highly reproducible and Antagomirs are incorporated to the same extent in all cells of a particular subset already after a short incubation period. In contrast, by conventional transfection- or electroporation-based methods, oligonucleotides are taken up by only by a fraction of the cells. Thus, we suggest the use of Antagomirs for miRNA inhibition in primary T and B cells as the method of choice in functional studies. We provide a typical work-flow in Table 1 and suggestions for managing experimental difficulties and troubleshooting are listed in Appendix A.

Author contribution

CH and RR established the protocol, designed and performed the experiments, analyzed the data and wrote the manuscript. JW and MP performed experiments. HDC and AR supervised the research and wrote the manuscript and MFM supervised the research, discussed the results, analyzed the data and wrote the manuscript.

Conflict of interest

The authors declare no conflicting interest in this work.
ProblemPossible reasonSolution
No phenotypical changeNo efficient silencing of specific miRNACheck for knockdown efficiency, if no knockdown can be observed, see “No change in miRNA levels” section
No impact on targetDivergent target expression profileCompare miRNA and target expression (mRNA and protein) kinetics and determine suitable analysis time point (impact on target mRNA and protein may vary)
No efficient silencing of specific miRNACheck for knockdown efficiency, if no knockdown can be observed, see “No change in miRNA levels” section
No change in miRNA levelsAntagomir does not have the correct specificity for the miRNAControl Antagomir sequence
No functional AntagomirMeasure concentration of Antagomir in stock solution to ensure it was not degraded during reconstitution and/or shipment
Always resuspend Antagomirs in RNase-free water, Antagomirs are extremely susceptible to RNase-mediated degradation
No efficient silencing by AntagomirIncrease Antagomir concentration (some miRNAs have a high abundance and may therefore need higher concentrations of Antagomirs or a later analysis time point for optimal knockdown effect)
Increase incubation time in FCS-free medium
Decrease cell number
Test different analysis time points (Antagomirs should enter cells already shortly after treatment. If analysis time point is very late, miRNA levels could be already restored. Alternatively, highly abundant miRNAs may need a longer time period to be sufficiently knocked down)
Divergent miRNA expression profileDefine the expression kinetics of miRNA to determine suitable analysis time point
Only mild change in miRNA levelsInefficient knockdownIncrease Antagomir concentration (some miRNAs have a high abundance in the cells and may therefore need higher concentrations of Antagomirs or a later analysis time point for optimal knockdown effect. In addition, strong stimuli lead to an exacerbated proliferation and dilution of the Antagomir)
Increase incubation time
Decrease cell number
Test different analysis time points (Antagomirs should enter cells already shortly after treatment. If analysis time point is very late, miRNA levels could be already restored. Alternatively, highly abundant miRNAs may need a longer time period to be sufficiently knocked down)
Antagomirs are competitively taken up by non-target cells in the cultureIncrease Antagomir concentration
Change the ratio of target cells to non-target cells
Remove non-target cells during Antagomir treatment
No miRNA detectionLoss of miRNA during RNA purificationUse miRNA-specific RNA prep system
Cells died during cultureCells are very sensitive to serum starvationDecrease incubation time
Treat with rich medium, e.g., medium supplemented with ITS liquid media (Sigma Life Science, Germany) supplement in the final cell culture medium
Titrate low amounts of serum into pulse medium to find optimal balance of miRNA knockdown and cell viability
Exchange medium to provide fresh nutrients
Decrease cell culture duration
  14 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Silencing of microRNAs in vivo with 'antagomirs'.

Authors:  Jan Krützfeldt; Nikolaus Rajewsky; Ravi Braich; Kallanthottathil G Rajeev; Thomas Tuschl; Muthiah Manoharan; Markus Stoffel
Journal:  Nature       Date:  2005-10-30       Impact factor: 49.962

3.  miR-221 redirects precursor B cells to the BM and regulates their residence.

Authors:  Marko Knoll; Szandor Simmons; Corinne Bouquet; Joachim R Grün; Fritz Melchers
Journal:  Eur J Immunol       Date:  2013-07-08       Impact factor: 5.532

4.  miR-148a promotes plasma cell differentiation and targets the germinal center transcription factors Mitf and Bach2.

Authors:  Martina Porstner; Rebecca Winkelmann; Patrick Daum; Julia Schmid; Katharina Pracht; Joana Côrte-Real; Sandra Schreiber; Claudia Haftmann; Andreas Brandl; Mir-Farzin Mashreghi; Kolja Gelse; Manuela Hauke; Ina Wirries; Markus Zwick; Edith Roth; Andreas Radbruch; Jürgen Wittmann; Hans-Martin Jäck
Journal:  Eur J Immunol       Date:  2015-03-12       Impact factor: 5.532

5.  Induced miR-99a expression represses Mtor cooperatively with miR-150 to promote regulatory T-cell differentiation.

Authors:  Sebastian C Warth; Kai P Hoefig; Anian Hiekel; Sonja Schallenberg; Ksenija Jovanovic; Ludger Klein; Karsten Kretschmer; K Mark Ansel; Vigo Heissmeyer
Journal:  EMBO J       Date:  2015-02-23       Impact factor: 11.598

6.  Bifunctional oligodeoxynucleotide/antagomiR constructs: evaluation of a new tool for microRNA silencing.

Authors:  Saskia Ziegler; Mariel Esther Eberle; Sabine J Wölfle; Klaus Heeg; Isabelle Bekeredjian-Ding
Journal:  Nucleic Acid Ther       Date:  2013-11-16       Impact factor: 5.486

7.  Inhibition of microRNA function by antimiR oligonucleotides.

Authors:  Jan Stenvang; Andreas Petri; Morten Lindow; Susanna Obad; Sakari Kauppinen
Journal:  Silence       Date:  2012-01-09

8.  Carrier-free cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group.

Authors:  Natalya S Petrova; Ivan V Chernikov; Mariya I Meschaninova; Iiya S Dovydenko; Aliya G Venyaminova; Marina A Zenkova; Valentin V Vlassov; Elena L Chernolovskaya
Journal:  Nucleic Acids Res       Date:  2011-11-10       Impact factor: 16.971

9.  Improved targeting of miRNA with antisense oligonucleotides.

Authors:  Scott Davis; Bridget Lollo; Susan Freier; Christine Esau
Journal:  Nucleic Acids Res       Date:  2006-05-11       Impact factor: 16.971

10.  Specificity, duplex degradation and subcellular localization of antagomirs.

Authors:  Jan Krützfeldt; Satoru Kuwajima; Ravi Braich; Kallanthottathil G Rajeev; John Pena; Thomas Tuschl; Muthiah Manoharan; Markus Stoffel
Journal:  Nucleic Acids Res       Date:  2007-04-16       Impact factor: 16.971

View more
  12 in total

1.  miRNA profiling of human naive CD4 T cells links miR-34c-5p to cell activation and HIV replication.

Authors:  Andreia J Amaral; Jorge Andrade; Russell B Foxall; Paula Matoso; Ana M Matos; Rui S Soares; Cheila Rocha; Christian G Ramos; Rita Tendeiro; Ana Serra-Caetano; José A Guerra-Assunção; Mariana Santa-Marta; João Gonçalves; Margarida Gama-Carvalho; Ana E Sousa
Journal:  EMBO J       Date:  2016-12-19       Impact factor: 11.598

Review 2.  HIV UTR, LTR, and Epigenetic Immunity.

Authors:  Jielin Zhang; Clyde Crumpacker
Journal:  Viruses       Date:  2022-05-18       Impact factor: 5.818

3.  Differential Expression of miRNAs in Trichloroethene-Mediated Inflammatory/Autoimmune Response and Its Modulation by Sulforaphane: Delineating the Role of miRNA-21 and miRNA-690.

Authors:  Nivedita Banerjee; Hui Wang; Gangduo Wang; Paul J Boor; M Firoze Khan
Journal:  Front Immunol       Date:  2022-03-29       Impact factor: 7.561

4.  Glycine confers neuroprotection through microRNA-301a/PTEN signaling.

Authors:  Juan Chen; Yang Zhuang; Zhi-Feng Zhang; Shu Wang; Ping Jin; Chunjiang He; Peng-Chao Hu; Ze-Fen Wang; Zhi-Qiang Li; Guang-Ming Xia; Gang Li; Yuan Wang; Qi Wan
Journal:  Mol Brain       Date:  2016-05-26       Impact factor: 4.041

Review 5.  MicroRNA as Therapeutic Targets for Chronic Wound Healing.

Authors:  Eoghan J Mulholland; Nicholas Dunne; Helen O McCarthy
Journal:  Mol Ther Nucleic Acids       Date:  2017-06-09       Impact factor: 8.886

6.  Leishmania donovani Activates Hypoxia Inducible Factor-1α and miR-210 for Survival in Macrophages by Downregulation of NF-κB Mediated Pro-inflammatory Immune Response.

Authors:  Vinod Kumar; Ajay Kumar; Sushmita Das; Ashish Kumar; Kumar Abhishek; Sudha Verma; Abhishek Mandal; Rakesh K Singh; Pradeep Das
Journal:  Front Microbiol       Date:  2018-03-08       Impact factor: 5.640

7.  Selective targeting of pro-inflammatory Th1 cells by microRNA-148a-specific antagomirs in vivo.

Authors:  Patrick Maschmeyer; Georg Petkau; Francesco Siracusa; Jakob Zimmermann; Franziska Zügel; Anja Andrea Kühl; Katrin Lehmann; Sarah Schimmelpfennig; Melanie Weber; Claudia Haftmann; René Riedel; Markus Bardua; Gitta Anne Heinz; Cam Loan Tran; Bimba Franziska Hoyer; Falk Hiepe; Sebastian Herzog; Jürgen Wittmann; Nikolaus Rajewsky; Fritz Georg Melchers; Hyun-Dong Chang; Andreas Radbruch; Mir-Farzin Mashreghi
Journal:  J Autoimmun       Date:  2017-12-01       Impact factor: 7.094

8.  Dysregulated miR-155 and miR-125b Are Related to Impaired B-cell Responses in Down Syndrome.

Authors:  Chiara Farroni; Emiliano Marasco; Valentina Marcellini; Ezio Giorda; Diletta Valentini; Stefania Petrini; Valentina D'Oria; Marco Pezzullo; Simona Cascioli; Marco Scarsella; Alberto G Ugazio; Giovanni C De Vincentiis; Ola Grimsholm; Rita Carsetti
Journal:  Front Immunol       Date:  2018-11-20       Impact factor: 7.561

9.  MicroRNA-31 Reduces the Motility of Proinflammatory T Helper 1 Lymphocytes.

Authors:  Markus Bardua; Claudia Haftmann; Pawel Durek; Kerstin Westendorf; Antje Buttgereit; Cam Loan Tran; Mairi McGrath; Melanie Weber; Katrin Lehmann; Richard Kwasi Addo; Gitta Anne Heinz; Anna-Barbara Stittrich; Patrick Maschmeyer; Helena Radbruch; Michael Lohoff; Hyun-Dong Chang; Andreas Radbruch; Mir-Farzin Mashreghi
Journal:  Front Immunol       Date:  2018-12-06       Impact factor: 7.561

10.  miR-23a-3p-abundant small extracellular vesicles released from Gelma/nanoclay hydrogel for cartilage regeneration.

Authors:  Hongxing Hu; Lanlan Dong; Ziheng Bu; Yifan Shen; Jian Luo; Hang Zhang; Shichang Zhao; Fang Lv; Zhongtang Liu
Journal:  J Extracell Vesicles       Date:  2020-06-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.